MicroPort MedBot - 微创机器人
"Explore unknown, shaping the era of super intelligent surgery."
Shanghai-listed surgical robotics company spanning endoscopy, orthopedics, vascular, natural-orifice and percutaneous robots, led by the Toumai system.
Shanghai MicroPort MedBot (Group) Co., Ltd. is a Chinese surgical robotics company that began developing laparoscopic surgical robots in 2014 as an internal incubation project of the MicroPort Group and was incorporated in Shanghai in 2015. The company develops comprehensive intelligent surgical solutions by integrating robot mechanics, control algorithms, electrical engineering, image-based navigation and precision imaging. MicroPort MedBot describes itself as covering five subsectors of surgical robotics—endoscopy (laparoscopy), orthopedics, pan-vascular intervention, trans-natural-orifice surgery and percutaneous puncture—plus medical aesthetics solutions. Its flagship Toumai laparoscopic surgical robot became the first domestic four-arm laparoscopic surgical robot approved by China's NMPA in 2022, received EU CE certification, and has been used in telesurgery including 5G ultra-remote and cross-border procedures; the SkyWalker orthopedic joint-replacement robot, Honghu orthopedic robot, DFVision 3D electronic laparoscope, Mona Lisa percutaneous puncture robot and the R-ONE vascular robot complete the portfolio.
Toumai has gained access in over 60 countries and regions and surpassed 100 cumulative global commercial orders by late 2025. The company was renamed Shanghai MicroPort Medbot (Group) Co., Ltd. in 2021 and listed on the Main Board of the Hong Kong Stock Exchange that year. Headquarters are at 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai.
Primary type & automation activities this supplier delivers:
Toumai Laparoscopic Surgical Robot
- Model: Toumai
- Launch Year: 2022
Four-arm laparoscopic surgical robot supporting 5G telesurgery; first domestic NMPA-approved system.
SkyWalker Orthopedic Surgical Robot
Hip and knee joint-replacement orthopedic surgical robot with NMPA certification and global use.
Honghu Orthopedic Surgical Robot
- Model: Honghu
- Launch Year: 2022
Chinese-developed orthopedic robot with proprietary robotic arms; NMPA, CE and FDA cleared.
DFVision 3D Electronic Laparoscope
- Model: DFVision
- Launch Year: 2021
3D electronic laparoscope for minimally invasive surgical imaging, NMPA and CE certified.
Contact MicroPort MedBot
WEBSITE
https://www.microport-medbot.comPHONE
+86 400 900 3155HEADQUARTERS
China
Company Facts
Founded
2015
Primary Role
Manufacturer
Company Size
-
Primary Region
Asia-Pacific
Annual Sales
-
Funding Stage
Public
Funding Total
-
Certifications & Memberships
Robotics: Modelling, Planning and Control Siciliano, Sciavicco, Villani & Oriolo — RSF Specialist Shelf · Book S6 of 6
Siciliano's single-narrative counterpart to the Springer Handbook: kinematics through force control and visual servoing in one consistent notation. 4/5.
AI for Science 2026: The Global Race for Scientific Discovery
2026 AI for Science landscape report: WAIC 2026 exhibitor breakdown, MIT Boltz-2 and CMU Coscientist case studies, US/China/EU policy comparison, Anthropic Claude Science, and US academic cautionary views.
2026H2 Robotics Events Briefing: Tailored Recommendations for Robotics Readers
Discover the ultimate directory of global robotics events in 2026. Tailored briefings for engineers, investors, and founders on humanoid robots, AI, and industrial automation by RobotToday.
Automate 2026 | Ubicept Explores Photon-Level Machine Vision
Ubicept demonstrated single-photon SPAD imaging at Automate 2026, achieving 140 dB HDR and >10 dB SNR gains for industrial robotics edge AI.
The EV Déjà Vu: Why China's Humanoid Robot Blitz May Be Winning the Battle — but Losing the War
China controls 80% of humanoid robot shipments and crushes hardware costs. But is winning the body enough? A deep analysis of the US-China robot war beyond the EV analogy.
ROBOTTODAY Weekly June 23 – 27, 2026
This week in robotics: Agility Robotics $2.5B SPAC deal for first humanoid IPO, BMW Figure 03 logistics deployment, Morgan Stanley doubles China humanoid forecast, ON Semiconductor acquires Synaptics for $7B, Sony halts aibo in Japan. June 23–27, 2026.
China’s medical AI breaks ground as surgical robot wins EU approval, model tops benchmark
Chinese medical AI has achieved significant advancements, highlighted by the entry of a teleoperated surgical robot into the European Union market and a clinical-grade model surpassing a key healthcare benchmark established by OpenAI. On Monday, Shanghai MicroPort MedBot announced that its Toumai Remote robot, designed for remote laparoscopic surgeries, has received the CE mark, a certification required for market access in the EU, as reported in its filing to the Hong Kong stock exchange. This development underscores the growing influence of Chinese innovations in the global healthcare technology sector, driven by the increasing demand for advanced surgical solutions that enhance precision and accessibility. The successful certification of the Toumai Remote robot marks a pivotal step in expanding its operational capabilities and improving patient outcomes in surgical procedures across Europe.
Capex Analysis 2025: AI Hyperscalers vs Humanoid Robots — Financing Risk Deep Dive
Compare how Microsoft, Google, Oracle, Tesla Optimus, Figure AI and UBTECH finance their Capex. Supply chain risk, ROIC analysis and a 3-dimension investment framework included.
CONSTRUCTION ROBOTICS | FUTURE HORIZONS: 2025–2030 & BEYOND
Construction robotics is entering its decisive decade. Autonomous jobsites, swarm coordination, humanoid integration, and a potential $60 billion market reshape every strategic decision in the industry.
ROBOTTODAY Weekly May 18 – 22, 2026
This week in robotics: Hyundai plans 25,000 Atlas robots for its factories, XPENG rolls off China’s first mass-produced L4 robotaxi, Singapore launches its first multi-operator physical AI testbed, and Kawasaki Heavy opens a Silicon Valley physical AI center with NVIDIA. May 18–22, 2026.
Chinese Surgical Robots Surpass Da Vinci in Domestic Market Share, Expanding into Global Remote Surgery
China's surgical robot industry has achieved a significant milestone, with the MicroPort MedBot Toumai surpassing the Da Vinci system in domestic market share from January to May 2026. This development marks a pivotal moment for the country's medical technology sector, showcasing its rapid advancements and growing competitiveness in the global market. Additionally, the MicroPort MedBot Toumai is leading the way in remote surgery, expanding its reach across multiple countries. This progress reflects China's commitment to innovation in healthcare technology and its ambition to establish a strong presence in the international surgical robotics arena.
News
GLOBAL ROBOTICS INDUSTRY Comprehensive Sector Overview
A comprehensive global robotics industry overview for 2025, analyzing 14 key market segments — from industrial and humanoid robots to logistics AMRs, military systems, and service robots — with expert market sizing, US case studies, five-year forecasts, and bilingual English-Chinese analysis for executives and investors.
